期刊文献+

1995—2011年云南省寻甸县乙型病毒性肝炎疫情动态分析 被引量:1

Dynamic analysis of epidemic of hepatitis B in Xundian County of Yunnan Province from 1995-2011
原文传递
导出
摘要 目的为进一步掌握寻甸县乙型病毒性肝炎(乙肝)疫情发展动态,为制定乙肝防治策略提供依据。方法对寻甸县1995—2011年乙肝疫情资料进行统计分析。结果寻甸县1995—2011年累计报告乙肝2 769例,乙肝发病率2009年以前呈上升趋势,其中发病率最高年份为2009年(为59.06/10万),从2010年开始逐步下降,已降至2011年的40.19/10万,年平均发病率为32.13/10万。乙肝发病年龄集中在15~40岁,占59.12%。职业构成比最高的为农民,占64.61%;最低为医务人员,占0.18%。结论寻甸县2009年以前乙肝报告发病率呈上升趋势,2010年开始呈逐步下降趋势。在下一步工作中,应进一步加强全县乙肝防治工作,应继续巩固新生儿乙肝疫苗接种工作,大力推广易感人群,尤其是青壮年乙肝疫苗接种工作,加强疫情监测,重视安全注射,进一步降低乙肝发病率。 [ Objective] To further understand the epidemic developments of hepatitis B in Xundian County of Yunnan Province, and provide evidence for developing hepatitis B control strategies. [ Methods ] The epidemic data of hepatitis B in Xudian County from 1995-2011 were analyzed statistically. [ Results] A total of 2 769 cases of hepatitis B were reported from 1995-2011, the incidence of hepatitis B showed upward tendency before 2009, with peak ( 59.06/100 000 } in 2009. It decreased gradually from 2010 and reached 40.19/100 000 in 2011, with average annual incidence rate of 32.13/100 000. Most hepatitis B patients aged 15-40 years, occupying 59.12%. For occupation, peasants occupied 64.61% and medical workers occupied 0.18%. [ Conclusion] The reported incidence of hepatitis B showed upward tendency before 2009 and downward tendency after 2010. It is necessary to further strengthen hepatitis control, to consolidate neonatal hepatitis B vaccination continuously, to prompt hepatitis B vaccination in sus- ceptible population, especially in young adults, to enhance epidemic surveillance, to focus on safe injection so as to reduce the in- cidence of hepatitis B in this county.
出处 《职业与健康》 CAS 2013年第8期985-987,共3页 Occupation and Health
  • 相关文献

参考文献2

二级参考文献35

  • 1梁晓峰,陈园生,王晓军,贺雄,陈丽娟,王骏,林长缨,白呼群,严俊,崔钢,于竞进.中国3岁以上人群乙型肝炎血清流行病学研究[J].中华流行病学杂志,2005,26(9):655-658. 被引量:967
  • 2邢玉兰 龚晓红 周绍莲.阻断围产期母婴传播最佳免疫方案的研究[J].中华实验和临床病毒学杂志,1990,4:485-488.
  • 3Strader DB,Wright T,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C.Hepatology,2004,39:1147-1171.
  • 4Seeger C,Mason WS.Hepatitis B virus biology.Microbiol Mol Biol Rev,2000,64:51-68.
  • 5Scaglioni PP,Melegari M,Wands JR.Biologic properities of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame.Virology,1997,233:374-381.
  • 6Lai CL,Dienstag J,Schiff E,et al.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Clin Infect Dis,2003,36:687-696.
  • 7Hu KQ.Occult hepatitis B virus infection and its clinical implications.J Viral Hepat,2002,9:243-257.
  • 8Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129.
  • 9World Health Organization.Hepatitis B.World Health Organization Fact Sheet 204 dex.(Revised October 2000).WHO Web site.http://www.who.int/mediacentre/ factsheets/fs204/en/ in html.
  • 10de FranchisR,Hadengue A,Lau G,et al.EASL International Consensus Conference on Hepatitis B.J Hepatol,2003,39 Suppll:S3-S25.

共引文献58

同被引文献12

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部